Advanced Therapy Developers Turn to Advisory Firms Earlier in the Development Process

A manufacturing decision made at the wrong stage or an incomplete development plan can slow an advanced therapy program long before it reaches patients. For organisations developing cell therapies, gene therapies and other complex treatments, many technical questions emerge well before commercial manufacturing enters the picture. That is changing when developers decide to bring consulting and advisory firms into the process.

More developers are involving external advisors during the early stages of development instead of waiting until major project milestones. The conversation has also shifted. Rather than asking consultants to solve a single technical issue, many organisations are looking for guidance that connects scientific development with the practical demands that come later.

Advanced therapies differ from conventional pharmaceutical products in several ways. They often rely on specialised manufacturing techniques and tightly controlled production processes. Choices made early in development can influence later work, including process transfer, manufacturing planning and supporting documentation. Even relatively small changes at the beginning of a program can create larger implications once production begins to scale.

That broader context has changed expectations for consulting and advisory firms. Their role is no longer limited to answering technical questions as they arise. Many developers now look for support in assessing development strategies, identifying potential implementation issues and preparing for the work that follows as programs advance.

The trend shows that making therapies is complicated. This is why some companies get help from outside. Many companies are still building their teams of scientists. They also know that sometimes it is good to get advice from people outside of their company. This is especially true when they are trying something with how they make things or when they have special needs for developing something. Advanced therapy development is the reason for this trend, not because companies want to outsource everything.

The need can be especially noticeable among smaller biotechnology companies. Early-stage developers often manage complex programs with limited internal resources. Reviewing technical plans with experienced advisors at an early point can help identify issues before they become expensive or difficult to correct.

Large pharmaceutical companies continue to use advisory firms as well, although the reasons may differ. Internal research and manufacturing teams may already have substantial experience, but outside specialists can offer an independent view of development plans or provide additional insight into technical decisions that affect later stages of a program.

The link between developers and advisory companies is also getting different. Instead of hiring experts for single tasks, a lot of companies keep them working through many parts of the project. This steady involvement helps keep the picture clear from one step to the next, cutting down on extra changes and making talks between teams more regular.

When evaluating advisory firms, buyers are paying closer attention to practical experience. Scientific expertise remains important, but many organisations also want advisors who understand how early development choices influence manufacturing activities and the documentation expected throughout regulated product development. Recommendations may be technically sound, yet they still need to work in day-to-day development settings.

When people are looking at firms, they really want to know about the firm's practical experience. It is still important for the advisory firms to have expertise, but a lot of organisations also want the advisors to understand how the choices they make early on can affect the manufacturing activities and the paperwork that is required for regulated product development. The advice that the advisors give may be correct, from a point of view, but advisory firms also need to make sure that the advice works in the real world when people are developing products every day.